Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.35 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | SLC13A5 | Q86YT5 | 6/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8154771 | 1.00 | ALDH1A1 (0.68) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| Water SCHEMBL26692025 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| Water SCHEMBL28198154 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| Water SCHEMBL25257573 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| Water SCHEMBL27742166 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| SCHEMBL27572383 | 0.98 | ALDH1A1 (0.71) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| SCHEMBL27588804 | 0.98 | ALDH1A1 (0.71) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| SCHEMBL934375 | 0.98 | ALDH1A1 (0.71) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| SCHEMBL144692 | 0.98 | ALDH1A1 (0.71) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R | |
| Hydrochloric Acid SCHEMBL28074367 | 0.96 | ALDH1A1 (0.62) | ALDH1A1SLC13A5HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12245995-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-03-11 | — | — | US | disclosed |
| US-12150921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4338804-A2 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2023-11-16 | — | — | US | disclosed |
| US-11723884-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20210361595-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210361594-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210346316-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2021-11-11 | — | — | US | disclosed |
| US-11000489-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| EP-1528933-B1 | PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION | ABBOTT BIOTECH LTD (BM) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011149412-A1 | INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | WO | disclosed |
| EP-2363145-A1 | Pharmaceutical anti-TNF-alpha antibody formulation | Abbott Biotechnology Ltd (BM) | 2011-09-07 | — | — | EP | disclosed |
| EP-2361637-A1 | Formulation of human antibodies for treating TNF-alpha associated disorders | Abbott Biotechnology Ltd (BM) | 2011-08-31 | — | — | EP | disclosed |
| CN-101381531-A | Five-layer pigment | MERCK PATENT GMBH (DE) | 2009-03-11 | — | — | CN | disclosed |
| CN-101104748-A | Multilayer pigments based on glass flakes | MERCK PATENT GMBH (DE) | 2008-01-16 | — | — | CN | disclosed |
| CN-1745740-A | Diffractive colorants for cosmetics | MERCK PATENT GMBH (DE) | 2006-03-15 | — | — | CN | disclosed |
| CN-1622981-A | Multilayer pigments based on glass flakes | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | CN | disclosed |
| CN-1470569-A | Five-layer pigment | 默克专利股份有限公司 | 2004-01-28 | — | — | CN | disclosed |
| WO-2000013502-A1 | FOLIAR FERTILIZER AND METHOD FOR USING THE SAME | YAMASHITA THOMAS T (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12245995-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-12150921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-11000489-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-20210361595-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-20210361594-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-12295921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-20210346316-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | CHRM1 522/4885ADRA1A 8/4885MEN1 1268/4885 |
| US-11723884-B2 | Epinephrine spray formulations | ADRB2, EPX, ADRB1 | CHRM1 372/4885ADRA1A 6/4885MEN1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.